Quick Answer
Aptevo Therapeutics Inc. reported Long-Term Debt of $1.46 million for fiscal year 2022.
Aptevo Therapeutics Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2022 | $1.46M | -60.7% |
| 2021 | $3.71M | -80.8% |
| 2018 | $19.28M | +22.6% |
| 2017 | $15.73M | -14.4% |
| 2016 | $18.38M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| December 31, 2022 | $1.46M | -60.7% | -23.8% |
| September 30, 2022 | $1.91M | — | -48.5% |
| December 31, 2021 | $3.71M | — | -81.0% |
| June 30, 2019 | $19.56M | +27.0% | +0.7% |
| March 31, 2019 | $19.41M | +38.9% | +0.7% |
| December 31, 2018 | $19.28M | +22.6% | +0.7% |
| September 30, 2018 | $19.14M | +9.5% | +24.3% |
| June 30, 2018 | $15.40M | -17.8% | +10.2% |
- Aptevo Therapeutics Inc. showed a decrease of -60.7% in Long-Term Debt compared to the prior fiscal year.
- Over the 2016–2022 period, Aptevo Therapeutics Inc.’s long-term debt has declined by 92.1% (from $18.38 million to $1.46 million).
- The most recent figure is from Aptevo Therapeutics Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 5, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: